XML 43 R20.htm IDEA: XBRL DOCUMENT
v3.22.1

Redeemable Convertible Preferred Stock | 12 Months Ended
--- | ---
Dec. 31, 2021
Temporary Equity Disclosure [Abstract] |
Redeemable Convertible Preferred Stock | 11. Redeemable Convertible Preferred Stock As of December 31, 2019, redeemable convertible preferred stock consisted of the following (in thousands, except per share and share amounts):
|  | Shares Authorized |  |  | Original Issuance price |  |  | Shares Issued and Outstanding |  |  | Liquidation Value |  |  | Proceeds Net of Issuance cost |
Series A |  |  | 909,312 |  |  | $ | 7.70 |  |  |  | 909,312 |  |  | $ | 7,001 |  |  | $ | 6,960 |
Series A-1 |  |  | 1,311,687 |  |  | $ | 8.84 |  |  |  | 1,311,687 |  |  |  | 11,595 |  |  |  | 11,548 |
Series B |  |  | 5,154,639 |  |  | $ | 17.46 |  |  |  | 5,154,632 |  |  |  | 90,000 |  |  |  | 84,472 |
Total |  |  | 7,375,638 |  |  |  |  |  |  | 7,375,631 |  |  | $ | 108,596 |  |  | $ | 102,980 |
In April and June of 2020, the Company issued a total of 4,200,353 shares of Series C redeemable convertible preferred stock at $18.00 per share for net proceeds of $72.5 million. Upon the closing of the Company's IPO on December 15, 2020, all outstanding redeemable convertible preferred stock automatically converted into shares of common stock and the related carrying value was reclassified to common stock and additional paid-in capital. There were no shares of redeemable convertible preferred stock outstanding as of December 31, 2021 and 2020. Funding Agreement with CFF — In April 2020, CFF made a $10.0 million investment in the Company's Series C redeemable convertible preferred stock financing. In return for the investment, CFF received shares of Series C redeemable convertible preferred stock, and the Company and CFF entered into a Funding Agreement ("the Funding Agreement"). Pursuant to the terms of the Funding Agreement, except in the event of a technical failure, the $10.0 million received from CFF will be used to advance the development program for 4D-710, the Company's lead product in cystic fibrosis, or any other therapeutic approved by the Program Advisory Group ("PAG") to alleviate pulmonary complications of cystic fibrosis ("the Funding Agreement Product"). CFF committed to provide an additional $4.0 million of funding upon acceptance of an Investigational New Drug ("IND") application or its equivalent to allow for human testing of the Funding Agreement Product ("Acceptance"). The IND was cleared by the U.S. Food and Drug Administration in October 2021, and CFF made the additional investment of $4.0 million in cash for the issuance of 125,715 shares of the Company's common stock to CFF. Except in the event of a technical failure, the Company is committed to providing an amount equal to the funding provided by CFF to be used solely to advance the Funding Agreement Product. A technical failure is defined as a determination by the Company, after consultation with and approval of the PAG that (i) the Funding Agreement Product has failed to reach its intended endpoints due to safety issues, lack of sufficient transgene expression and/or efficacy, each despite commercially reasonable efforts and (iii) the exercise of further commercially reasonable efforts is unlikely to correct such failure. Under the terms of the Funding Agreement, neither the $10.0 million investment in the Series C redeemable convertible preferred stock, which converted to common stock as of December 31, 2020, nor the $4.0 million of funding upon Acceptance are restricted as to withdrawal or usage.

X
- Definition Temporary equity disclosure. + References No definition available. + Details
Name: | fdmt_TemporaryEquityDisclosureTextBlock
Namespace Prefix: | fdmt_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_TemporaryEquityDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration